Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL) (Aurora)

8 luglio 2026 aggiornato da: Lu Huaiwu, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

A Prospective, Open-label, Randomized, Controlled, Non-inferiority Phase II Study Comparing HAL-PDT With Deferred Surgery Versus Immediate Surgery in Subjects With High-grade Squamous Intraepithelial Lesions (HSIL)

High-grade squamous intraepithelial lesions (HSIL), encompassing cervical intraepithelial neoplasia grade 2 (CIN2) with p16 positivity and grade 3 (CIN3), are precancerous conditions that require effective intervention. This Phase II study aims to comprehensively evaluate the efficacy, safety, and impact on quality of life of hexaminolevulinate photodynamic therapy (HAL-PDT) with deferred surgery compared to immediate surgical treatment in subjects with HSIL.

This is a prospective, open-label, randomized, controlled, non-inferiority trial. A total of 230 subjects are planned to be enrolled, with 115 subjects allocated to each treatment group (HAL-PDT with Deferred Surgery or Immediate Surgery ).

The primary endpoint is the pathological regression rate at 12 months, defined as histological findings of normal tissue or low-grade squamous intraepithelial lesions (LSIL) via colposcopy-directed biopsy. Key secondary endpoints include Human Papillomavirus (HPV) clearance rates at 6 and 12 months, pathological regression rate at 6 months, quality of life assessed by the EORTC QLQ-CX24 questionnaire, safety profiles (incidence, severity, and duration of AEs and SAEs, as well as their relationship to the study treatments), and the proportion of subjects developing cervical cancer within 12 months.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

High-grade squamous intraepithelial lesions (HSIL), encompassing cervical intraepithelial neoplasia grade 2 (CIN2) with p16 positivity and grade 3 (CIN3), are well-established precursors to invasive cervical cancer. Immediate excisional procedures such as loop electrosurgical excision procedure (LEEP) or cold knife conization remain the standard of care; however, they are associated with significant long-term morbidities, including cervical stenosis, cervical incompetence, and adverse obstetric outcomes in women of childbearing age. Hexaminolevulinate photodynamic therapy (HAL-PDT) is a non-invasive, tissue-preserving modality that offers a potential alternative.

This Phase II trial is designed to test the hypothesis that HAL-PDT (HAL-PDT Q2W×6 ) with deferred surgery achieves a 12-month pathological regression rate non-inferior to that of immediate surgery, while providing a favorable safety and quality-of-life profile.

A total of 230 subjects are planned for enrollment, with 115 allocated to each treatment arm. The primary efficacy analysis will be performed on both the Intention-to-Treat (ITT) and Per-Protocol (PP) populations to test the non-inferiority margin, which is pre-specified based on clinically acceptable thresholds. Safety analyses will be conducted on the Safety Set (SS).

Tipo di studio

Interventistico

Iscrizione (Stimato)

230

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Fujian
      • Fuzhou, Fujian, Cina, 350001
        • Fujian Medical University Union Hospital
        • Contatto:
          • Ethics Committee Administrator
          • Numero di telefono: 0591-83357896
          • Email: fjxhe_irb@163.com
        • Investigatore principale:
          • Dezhao Chen, MD, PhD
      • Fuzhou, Fujian, Cina, 350005
        • The First Affiliated Hospital of Fujian Medical University
        • Contatto:
          • Ethics Committee Administrator
          • Numero di telefono: 0591-87982001
          • Email: fdyy_irb@163.com
        • Investigatore principale:
          • Lihong Chen, MD, PhD
      • Xiamen, Fujian, Cina, 361001
        • Xiamen Maternity and Child Healthcare Hospital
        • Contatto:
          • Ethics Committee Administrator
          • Numero di telefono: 0592-2662920
          • Email: xmfyllwyh@163.com
        • Investigatore principale:
          • Qing Li, MD, PHD
      • Xiamen, Fujian, Cina, 361003
        • he First Affiliated Hospital of Xiamen University
        • Contatto:
          • Jiajie Lin
          • Numero di telefono: +86-0592-2137569
          • Email: xdfyec@163.com
        • Investigatore principale:
          • Qionghua Chen, MD, PHD
    • Guangdong
      • Foshan, Guangdong, Cina, 528000
        • The First People's Hospital of Foshan
        • Contatto:
        • Investigatore principale:
          • Lijiang Xu, MD, PHD
      • Foshan, Guangdong, Cina, 528300
        • Foshan Shunde Maternal and Child Health Hospital
        • Contatto:
        • Investigatore principale:
          • Jinzhi Huang, MD, PHD
      • Guangzhou, Guangdong, Cina, 510280
        • Zhujiang Hospital, Southern Medical University
        • Contatto:
          • Ethics Office Administrator
          • Numero di telefono: +86-020-62783372
          • Email: zjyygcp@163.com
        • Investigatore principale:
          • Xuefeng Wang, MD, PhD
      • Guangzhou, Guangdong, Cina, 510010
        • Guangdong Women and Children Hospital
        • Contatto:
        • Investigatore principale:
          • Xiaoli Sun, MD, PHD
      • Guangzhou, Guangdong, Cina, 510095
        • The Affiliated Cancer Hospital of Guangzhou Medical University
        • Contatto:
        • Investigatore principale:
          • Bin Wen, MD, PhD
      • Guangzhou, Guangdong, Cina, 510120
        • Guangdong ProvincialHospital of Chinese Medicine
        • Contatto:
          • Administrator Ethics Committee
          • Numero di telefono: 020-81887233-35943
          • Email: Ilbgs@gzucm.edu.cn
        • Investigatore principale:
          • Jing Xiao, MD, PhD
      • Guangzhou, Guangdong, Cina, 510180
        • Guangzhou First People's Hospital (The Second Affiliated Hospital of South China University of Technology)
        • Contatto:
          • Ethics Committee Administrator
          • Numero di telefono: 020-81045412
          • Email: MEC_GZSY@126.com
        • Investigatore principale:
          • Yan Kuang, MD, PhD
      • Guangzhou, Guangdong, Cina, 510317
        • Guangdong Second Provincial GeneralHospital (Guangdong Provincial Emergency Hospital)
        • Contatto:
          • Administrator Clinical Research Office
          • Numero di telefono: +86-20-89168338
          • Email: gdech_irb@163.com
        • Investigatore principale:
          • Xiafei Fu, MD, PhD
      • Guangzhou, Guangdong, Cina, 510405
        • The First AffiliatedHospital, Guangzhou University ofTraditional Chinese Medicine
        • Contatto:
          • Ethics Committee Administrator
          • Numero di telefono: +86-20-36588667
          • Email: gztcmlunli@163.com
        • Investigatore principale:
          • Sijin Li, MD, PhD
      • Guangzhou, Guangdong, Cina, 510623
        • Guangzhou Women and Children's Medical Center (The Affiliated Women and Children's Medical Center of Guangzhou Medical University)
        • Contatto:
          • Ethics Committee Administrator
          • Numero di telefono: 020-81886332
          • Email: gzwc_irb@163.com
        • Investigatore principale:
          • Kun Shi, MD, PhD
      • Guangzhou, Guangdong, Cina, 511400
        • Panyu Central Hospital Affiliated to Guangzhou Medical University
        • Contatto:
          • Ethics Committee Administrator
          • Numero di telefono: 020-34858888
          • Email: pyzxylunli@163.com
        • Investigatore principale:
          • Xiang Yang, MD, PhD
      • Shenzhen, Guangdong, Cina, 518036
        • Peking University Shenzhen Hospital
        • Contatto:
          • Ethics Committee Administrator
          • Numero di telefono: 0755-83923333
          • Email: pkuszh_irb@163.com
        • Investigatore principale:
          • Zhihong Liu, MD, PhD
      • Shenzhen, Guangdong, Cina, 518031
        • Shenzhen Maternity and Child Health Hospital
        • Contatto:
        • Investigatore principale:
          • Ping Jin, MD, PHD
      • Zhongshan, Guangdong, Cina, 510080
        • The First Affiliated Hospital, Sun Yat-sen University
        • Contatto:
        • Investigatore principale:
          • Mian He, MD, PHD
        • Investigatore principale:
          • Junxiu Liu, MD, PHD
    • Guangxi
      • Nanning, Guangxi, Cina, 530021
        • The First Affiliated Hospital of Guangxi Medical University
        • Contatto:
        • Investigatore principale:
          • Jiangtao Fan, MD, PhD
      • Nanning, Guangxi, Cina, 530000
        • Guangxi Zhuang Autonomous Region Maternal and Child Health Hospital
        • Contatto:
        • Investigatore principale:
          • Chunqiu Xiong, MD, PHD
    • Guangzhou
      • Dongguan, Guangzhou, Cina, 523000
        • Dongguan Maternal and Child Health Care Hosptial
        • Contatto:
        • Investigatore principale:
          • Ping Zhou, MD, PHD
    • Henan
      • Zhengzhou, Henan, Cina, 450052
        • The First Affiliated Hospital of Zhengzhou University
        • Contatto:
          • Ethics Committee Administrator
          • Numero di telefono: 0371-66278510
          • Email: zdyyllwy@163.com
        • Investigatore principale:
          • Liping Han, MD, PhD
    • Jiangsu
      • Nanjing, Jiangsu, Cina, 210029
        • The First Affiliated Hospital with Nanjing Medical University (Jiangsu Provincial People's Hospital)
        • Contatto:
          • Ethics Committee Administrator
          • Numero di telefono: 025-68136360
          • Email: jsphkj@163.com
        • Investigatore principale:
          • Xiaoling Ma, MD, PhD
    • Jinlin
      • Changchun, Jinlin, Cina
        • The First Hospital of Jilin University
        • Contatto:
        • Investigatore principale:
          • Songling Zhang, MD, PHD
    • Liaoning
      • Shenyang, Liaoning, Cina, 110016
        • The General Hospital of Northern Theater Command of the Chinese People's Liberation Army
        • Contatto:
          • Ethics Committee Administrator
          • Numero di telefono: 024-28851114
          • Email: btzzyy_irb@163.com
        • Investigatore principale:
          • Lipeng Pei, MD, PhD
    • Shanxi
      • Taiyuan, Shanxi, Cina, 030000
        • Shanxi Provincial People's Hospital
        • Contatto:
        • Investigatore principale:
          • Yuping Suo, MD, PHD
    • Sichuan
      • Chengdu, Sichuan, Cina, 610041
        • The West China Second University Hospital of Sichuan University
        • Contatto:
        • Investigatore principale:
          • Yuedong He, MD, PHD
    • Zhejiang
      • Hangzhou, Zhejiang, Cina, 310022
        • Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
        • Contatto:
        • Investigatore principale:
          • Yichen Wang, MD, PhD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Bambino
  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • Voluntarily participate in this clinical study, fully understand the study content, procedures, and potential adverse reactions, and be able to sign the written informed consent form.
  • Able to complete the study in accordance with the study protocol.
  • Subject age ≥18 years.
  • Presence of High-Grade Squamous Intraepithelial Lesion (HSIL) (CIN2 P16 positive/CIN3), specifically: HSIL with histopathological diagnosis of grade II/III (CIN2 P16 positive/CIN3) within 3 months prior to the first treatment.
  • Adequate colposcopy, including: (a) Complete visibility of the cervical transformation zone, including the squamocolumnar junction; (b) Complete visibility of lesion margins.
  • The investigator determines that non-surgical treatment is acceptable for the participant.
  • The investigator determines that the cervical size is suitable for placement of the HAL-PDT device.
  • Meets the following conditions: Women of childbearing potential (WOCBP) must have a negative serum pregnancy test result prior to the start of treatment. No plan for pregnancy during the study period; no sexual activity or use of effective and reliable contraception from the end of the last menstrual period to the start of the study, and agreement to use condoms for barrier contraception during the study period. WOCBP is defined as a female who has experienced menarche, has not undergone hysterectomy or bilateral oophorectomy, and has not reached natural menopause (i.e., no menstruation at all for the past 24 consecutive months).

Exclusion Criteria:

  • Cervical adenocarcinoma in situ or other glandular lesions, invasive cervical cancer, or suspected malignant lesions.
  • CIN2 with P16 negative.
  • Lesions extending to the vaginal wall, cervical canal, or vaginal fornix, or lesions located on the vulva.
  • Prior physical or surgical treatment to the cervix resulting in incomplete cervical structure (e.g., cold knife conization), or receipt of physical or surgical therapy for CIN2 or CIN3 after the current histopathological diagnosis.
  • The first study treatment day falls within 7 half-lives of the last antiviral medication.
  • Severe pelvic inflammatory disease, severe cervicitis, or other severe gynecological infectious diseases found on colposcopic or clinical examination.
  • Investigator judges that vaginal bleeding during treatment may affect treatment outcomes.
  • Receipt of any inactivated vaccine within 2 weeks prior to the first treatment, or any live vaccine within 4 weeks prior to the first treatment.
  • Previous severe cardiovascular, cerebrovascular, neurological, psychiatric, endocrine, or hematopoietic disease that has not been cured; known severely compromised immune function, or need for long-term use of corticosteroids or immunosuppressants; history of malignancy within 5 years.
  • History of clinically significant immunosuppression or confirmed autoimmune disease; or primary immunodeficiency.
  • Known or newly identified active sexually transmitted diseases (STDs), including but not limited to HIV, syphilis, genital herpes, unless adequately treated and tested negative before study treatment.
  • Presence of a cardiac pacemaker.
  • Suspected or known porphyria, or known allergy to the study drug, its chemically similar compounds, or photosensitizers.
  • Allergy to silicone.
  • Pregnant or breastfeeding women.
  • Delivery or miscarriage within 6 weeks prior to enrollment.
  • Participation in any other clinical trial within 30 days prior to study treatment.
  • Poor compliance or judged by the investigator to be unsuitable for participation in this clinical study.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Hexaminolevulinate Photodynamic Therapy (HAL-PDT) with Deferred Surgery
Subjects receive Hexaminolevulinate Photodynamic Therapy (HAL-PDT) once every 2 weeks (Q2W) for a total of 6 treatment sessions. At 6 months after the first treatment, participants undergo colposcopy-directed cervical biopsy and HPV testing to assess treatment response. Those who achieve pathological remission (normal or LSIL) enter follow-up without surgery. Those who do not achieve remission (persistent HSIL or disease progression) receive standard surgical treatment (LEEP or CKC) within 4 weeks of the 6-month assessment.
HAL-PDT is a drug-device combination product. The drug is hexaminolevulinate hydrochloride (HAL) 5% ointment. The device is a single-use cervical light delivery device (CL7) with integrated red LEDs. The ointment is applied into the device cup, placed against the cervix for 5 hours of drug absorption, then automatically delivers 125 J/cm² photodynamic therapy for 4 hours and 36 minutes. Total in-situ time is 11-24 hours. Patients remove the device themselves. Treatment regimen: one session every 2 weeks for a total of 6 sessions (Q2W × 6).
Comparatore attivo: Immediate Surgery
Participants with histologically confirmed HSIL (CIN2 P16 positive/CIN3) receive standard surgical treatment (LEEP or CKC) per routine clinical practice. Follow-up assessments include HPV testing and colposcopy-directed cervical biopsy at 6 months and 12 months post-surgery to evaluate pathological remission and HPV clearance rates. Safety monitoring is conducted from signing of informed consent through the end of study.
Subjects undergo immediate surgical excision of the cervical lesion via either Loop Electrosurgical Excision Procedure (LEEP) or Cold Knife Conization (CKC), as determined by the investigator based on the subject's individual lesion characteristics, size, and clinical presentation, following standard institutional surgical protocols.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Histopathological regression rate at 12 months
Lasso di tempo: 12 months after the first treatment
Proportion of participants with pathological remission on colposcopy-directed cervical biopsy at 12 months after the first treatment. Pathological remission is defined as histopathological finding of normal tissue or low-grade squamous intraepithelial lesion (LSIL)
12 months after the first treatment

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Pathological remission rate at 6 months
Lasso di tempo: 6 months after the first treatment
Proportion of participants with pathological remission on colposcopy-directed cervical biopsy at 6 months after the first treatment. Pathological remission is defined as histopathological finding of normal tissue or low-grade squamous intraepithelial lesion (LSIL).
6 months after the first treatment
HPV baseline clearance rate at 12 months
Lasso di tempo: 12 months after the first treatment
Proportion of participants with clearance of baseline high-risk HPV subtypes at 12 months after the first treatment. HPV clearance is defined as undetectable of the same high-risk HPV subtype(s) that were present at baseline.
12 months after the first treatment
Incidence of cervical cancer at 12 months
Lasso di tempo: 12 months after the first treatment
Proportion of participants with histologically confirmed cervical cancer (any stage) diagnosed within 12 months after the first treatment.
12 months after the first treatment
Human Papillomavirus (HPV) baseline clearance rate at 6 months
Lasso di tempo: 6 months after the first treatment
Proportion of participants with clearance of baseline high-risk Human Papillomavirus (HPV) subtypes at 6 months after the first treatment. HPV clearance is defined as undetectable of the same high-risk HPV subtype(s) that were present at baseline.
6 months after the first treatment
Quality of life assessed by EORTC QLQ-CX24
Lasso di tempo: 12 months after the first treatment
Quality of life assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Cervical Cancer Module (EORTC QLQ-CX24). Scores for each domain are linearly transformed to a 0-100 scale. For global health status and functional domains, a higher score indicates a better outcome (better quality of life/function). For symptom scales, a higher score indicates a worse outcome (more severe symptoms).
12 months after the first treatment
Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
Lasso di tempo: From informed consent through 12 months after the first treatment
Incidence, type, severity (mild, moderate, severe), duration, and relatedness to photodynamic therapy and/or surgical treatment of adverse events (AEs) and serious adverse events (SAEs) occurring from signing of informed consent through the end of study follow-up.
From informed consent through 12 months after the first treatment

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 luglio 2026

Completamento primario (Stimato)

16 giugno 2029

Completamento dello studio (Stimato)

16 giugno 2029

Date di iscrizione allo studio

Primo inviato

21 giugno 2026

Primo inviato che soddisfa i criteri di controllo qualità

21 giugno 2026

Primo Inserito (Effettivo)

25 giugno 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

9 luglio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

8 luglio 2026

Ultimo verificato

1 luglio 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .